Newest
-
Chinese enterprise initiates major irrigation project in Timor-Leste, boosting agriculture and strengthening bilateral bonds
-
Focus on Europe: Carronade Capital Management's Market Expansion Strategy
-
Carronade Capital Management Announces Expansion into Europe, Deepening its Services for Global High Net Worth Clients and Family Offices
-
Deliberation Meeting on Global Forest Environment Standards and Forest Environment Index was held at One Heung Kong, with China’s Solutions Elevated to Global Standards
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
2024-11-01
I-Mab Biopharma
HaiPress
ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com